CEO

Post-MVP Launch Management Changes: Henry Ines to stay on in Emeritus role; Axel Schumacher to return as CEO

CEO

Shivom Ventures Limited announced today Henry Ines will restore Axel Schumacher as Chief Executive Officer and stay on as CEO Emeritus. Additionally, Shivom has tapped Nate Raine for the Chief Operation Officer role and for Meer Ali to become the Chief Technology Officer.

London, United Kingdom – 8th August – Shivom announced today that Henry Ines has decided to step down and restore Axel Schumacher as acting Chief Executive Officer of Shivom. Henry will stay on as CEO Emeritus acting in an advisory role for Shivom post-MVP platform release. It’s been a little over a year since Henry Ines stepped into the CEO role and during his tenure with Shivom, he has managed to take both founders vision and create a product which can massively disrupt the genomics industry. Additionally, Henry has brought countless partnerships and pilot projects to Shivom such as Lifebit, H2020, CC-TDI, Family Care Path and more. “It’s been a great honor to work closely with our global team to build a highly innovative clinical SaaS platform and consumer genomics marketplace, which combined we believe are poised to disrupt the clinical research, drug discovery and personalized healthcare spaces. I stepped up as CEO in 2018 to help the team focus on execution and to navigate through an especially difficult post-ICO period, when the project was not only at its infancy, but the broader crypto industry was also experiencing significant challenges. Twelve months later, we have persevered and now have a fully functional world-class patient-centric MVP product, unparalleled ‘3 clicks’ integrated bioinformatics analysis capability, dynamic consent & permissions via smart contracts, a blockchain-based immutable consent audit trail functionality, established multiple strategic and complementary partnerships globally, a consumer marketplace with curated ‘best of breed’ personalized care products, demonstrated OMX token utility via payments and gamification/rewards, and have commenced with onboarding of initial customers, pilots, and monetization via our established business model. With these and many other accomplishments, I felt post MVP launch was the appropriate juncture for me to step down for new leadership to guide the next phase of the project. I have full confidence in the team and the excellent trio of Axel, Nate, and Meer, whom collectively have more than 50+ years of diverse operational, clinical, technical and startup experiences to take the business to the next level,” said Henry Ines, CEO Emeritus.

Axel Schumacher has led the Science and R&D team for the past year since Henry Ines took over his previous position. During his tenure as CSO, he was responsible for integrating bioinformatics partners and championing solutions for pilot projects ranging from Children’s Cancer to Medicinal Cannabis. Axel has an excellent track record with leading pharmaceutical companies and research organizations globally. He will return to his previous position and help the company scale and steer Shivom forward into the genomic landscape by utilizing his impressive 30+ years of experience working in the industry.”As we enter into this next critical stage, I am thrilled to lead the team, focusing on tackling the many problems associated with the global healthcare system through genomics. Returning as CEO, I will utilize my industry knowledge with pharma and make sure the team continues on the trajectory Henry has worked so hard to put us on. We are looking forward to being able to empower researchers by providing them with the tools to discover much deeper insights in half the time traditional analysis would take. Additionally, enabling individuals to better manage their health and wellness through Shivom’s secure blockchain-based technology platform and healthcare ecosystem,” said Axel Schumacher, Chief Executive Officer.

Lastly, Nate Raine has been tapped for the Chief Operating Officer (COO) role and lead operations out of Shivom’s London head office. Leveraging his deep background in startup operations, business development and scaling various solutions for enterprise organizations, Shivom will be poised for significant growth in the coming year. Meer Ali has also been elevated to the role of Chief Technology Officer (CTO). With his 20+ years of deep technical experiences, Meer will continue to oversee and lead Shivom’s product development efforts, while helping to grow the company’s technical team and footprint globally. The management team and advisors believe these roles reflect the most direct path to success for a post-platform released Shivom.

A successor to the role of Director, Marketing & Communications will be announced shortly. The team is thankful for the continued support of its partners, investors, and community.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data discovery and analysis company optimizing the way DNA is shared, secured and analyzed. By utilizing innovative technologies such as blockchain and machine-learning algorithms, we are able to democratize genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratization of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recent Updates

View All

Hepatoblastoma

Shivom and cc-TDI to Advance Clinical Research for Hepatoblastoma & Other Rare Pediatric Diseases

Hepatoblastoma

Shivom Ventures Limited (“Shivom”) and Children’s Cancer Therapy Development Institute (“cc-TDI”) enter into a Memorandum of Understanding (MOU) to explore a partnership for advancing clinical research and drug discovery for rare pediatric genetic diseases.

LONDON and PORTLAND – July 10, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has signed an MOU with cc-TDI, a unique non-profit organization focused on the ‘preclinical gap’ in childhood cancer research. The two entities will explore a partnership empower families with precision medicine solutions and community-driven data sharing for children suffering from Hepatoblastoma Tumors.  This approach is the next evolutionary step of the “It’s my Data” movement that makes patients into citizen-scientists (https://www.wsj.com/articles/SB10001424052970204621904577014330551132036).

Through this MOU, Shivom will utilize their AI and Blockchain powered patient recruitment platform and dynamic permissions & consent features to help cc-TDI to develop preclinical and eventual clinical solutions to combat this rare disease. Hepatoblastoma is a very rare cancerous tumour that starts in the liver. This disease primarily affects children from infancy to approximately 3 years of age. To date, developing a cure or new therapies is increasingly difficult because of the lack of Hepatoblastoma Genomes sequenced, partly pertaining to how extremely rare these genomes are and the subject matter of sequencing DNA from children below the ages 5. Shivom will leverage its global affiliate network and innovative clinical research & recruitment platform to help break these barriers in order to bring awareness and help make parents and legal guardians full partners in research for cures. “Shivom is proud to support cc-TDI with its critically important drug development research work to include tackling rare pediatric diseases such as hepatoblastoma, the most common primary liver tumor diagnosed in childhood. We plan to leverage our unique technology solutions and global recruitment platform to drive awareness and ultimately aim to secure the additional datasets and tissue samples needed to advance clinical research and expedite the delivery of a cure for hepatoblastoma and other rare genetic diseases afflicting children globally.” said Henry Ines, Chief Executive Office of Shivom.

To date, cc-TDI and its colleagues worldwide have collected less than 150 children’s hepatoblastoma tumours to determine DNA mutations and RNA-based gene expression. This is significantly low; researchers need more information in order to better understand the full range of mutations in this cancer. “Hepatoblastoma can have an outstanding outcome if surgery can remove the tumor, yet for those with refractory, metastatic or relapsed disease – the options are few.  The number of drug targets carefully explored for these desperate patients over ten years is less than a half-dozen, and primarily because so few datasets exist for patients with advanced disease.  The voucher system to be offered by Shivom, and the way in which the Shivom platform puts patients in control of data sharing represents a cultural shift in the precision medicine and the search for hepatoblastoma cures.”

About Shivom
Shivom is a biotechnology and precision medicine company optimising the way healthcare data is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to drive clinical efficiencies and democratise genomics.

Our mission is to bring exponential value to our end-users within the global genetics and precision medicine ecosystem. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here
Learn more about our genetic counselling pilot here
Learn more about the TranSYS grant here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Children’s Cancer Therapy Development Institute
The Children’s Cancer Therapy Development Institute (cc-TDI, www.cc-tdi.org) is a unique non-profit organization focused on the ‘preclinical gap’ in childhood cancer research. Our mission is to bridge scientific discovery and the initiation of clinical trials. Through our efforts, we will provide evidence-based testing for the selection of new drugs to be used in childhood cancer clinical trials, thus seeding pediatric Phase I and II trials. This concept was emphasized in the Institute of Medicine Report, Making Better Drugs for Children with Cancer in 2005. Our longstanding work with mouse models of brain tumors and sarcomas is the cornerstone for basic science & target discovery and our mission. The cc-TDI research team is led by Scientific Director Dr. Charles Keller who follows in the footsteps of his mentor, 2007 Nobel laureate Mario Capecchi. The cc-TDI laboratory is based on the premise of a non-profit multidisciplinary biotech and is thus located in between the Silicon Forest in Beaverton, OR (Intel Headquarters) and the Portland-area medical center. Our industrial-modern 4600 ft2 BSL wet lab facility is a former 70-year old paint factory remodeled by Nike as an off-site creative space – an ideal setting to spark innovation.

Recent Updates

View All

genetic counselling

Shivom and Family Care Path Launch Genetic Counselling Pilot

genetic counselling

Shivom Ventures Limited and Family Care Path have launched a Genetic Counselling Pilot in order to help patients from the United States have a deeper understanding of their genetic information through testing, counselling and the ties to family health history

London, United Kingdom and Cleveland, Ohio – July 1st, 2019 – Shivom Ventures Limited (“Shivom”), a biotechnology data and analysis company optimizing the way DNA is shared, secured and analyzed through blockchain and AI technology, and Family Care Path (FCP), a spin-off company from Cleveland Clinic, adapting and marketing web-based clinical decision support applications, have launched a telemedicine genetic counselling pilot today.

Shivom and Family Care Path will offer patients who have a family history of Cancer, Diabetes and or Cardiovascular issues genetic counselling sessions through CarePathConnect. These sessions will be available to purchase from Shivom’s shop for 1,000 tokens later next month. Following purchase, customers will be redirected to FCP’s MyLegacy application where they will be asked to fill out a unique health questionnaire. After the questionnaire has been completed, the patients will receive a Risk Assessment Report; this report will provide patients with an overview of their risk of inheriting certain genetic conditions. Once the patient has received their Risk Assessment Report they will be able to schedule a genetic counselling session with one of Family Care Path’s Genetic Counsellors. The pilot will only be available to patients who are living within the United States at this time.

 “We are excited to partner with the unique offerings of Shivom to provide individuals with powerful information to understand their family health history tied to genetic and hereditary risks. Our genetic risk tool, MyLegacy, combined with the support of genetic counselors provides expanded depth to the blockchain and AI capabilities of Shivom. We are confident this dynamic information will be insightful and beneficial to the end-users and their physicians,” said David McKee, CEO and President of Family Care Path.

 “For those who may be predisposed to or have a family history of cancer, diabetes or heart disease, undergoing genomic sequencing to gain additional insights may prove to be invaluable,” said Henry Ines, Chief Executive Officer of Shivom. “That said, interpreting sequencing results and understanding the appropriate therapeutic course of action may be challenging without the proper guidance from genomic counsellors. Accordingly, we are thrilled to work with Family Care Path, which maintains a network of certified, licensed clinical genetic counselors, who through the use of FCP’s proprietary risk assessment tools and its HIPAA compliant video telemedicine platform are able to help patients on a variety of critical matters ranging from better understanding potential risks associated with certain hereditary conditions, managing their health & wellness, mitigating against health risks to assessing the need for ordering additional genetic tests. We are excited to offer these additional resources to our customers in the US; eventually globally.”

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimizing the way DNA is shared, secured and analyzed. By utilizing innovative technologies such as blockchain and machine-learning algorithms, we are able to democratize genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratization of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Family Care Path
Family Care Path develops, adapts and markets web-based clinical software applications designed to improve patient outcomes, increase physician and clinical process efficiency, and interface with a variety of electronic health records.

Many exciting concepts for healthcare applications remain isolated within the development environment. Our company’s mission is to identify these opportunities and develop software solutions utilizing industry standard protocols, to enable widespread adoption.

We utilize the latest technology to develop secure and scalable applications to improve the quality of healthcare and reduce cost. Leveraging industry standard technologies such as Microsoft Cloud and both the SMART® and HL7® FHIR® open standards, Family Care Path creates applications which can seamlessly communicate with all electronic health record systems.

For more information about Family Care Path please visit:

www.familycarepath.com

Recent Updates

View All

horizon 20/20

Shivom Joins Consortia on Horizon 20/20 TranSYS €EUR4 Million Grant

horizon 20/20

Shivom joins European consortia of clinical and innovative tech organisations on Horizon 20/20 TranSYS Programme. The 4 Million Grant will be used to fund 15 Early Stage Research (“ESR”) projects.

London, United Kingdom – June 27, 2019 – Shivom Ventures Limited (“Shivom”), a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, joins European consortium of clinical and innovative tech organisations on Horizon 20/20 TranSYS Programme. The EUR4 Million Grant will be used to fund 15 Early Stage Research (“ESR”) projects seeking to advance and improve diagnostics, disease risk and treatment management, clinical sampling and more targeted therapeutic areas.

TranSYS research projects focus on “Integrating Big Data and ICT Solutions” and “Translating Basic to Clinical Research”. These areas are highlighted in the International Consortium for Personalised Medicine (ICPerMed) 2017 Action Plan4 as key challenges to develop new diagnostics, treatments, and healthcare approaches, to benefit European citizens and society. Part of the funds from the grant will be set aside for Shivom to work with each of these ESR’s to implement Shivom’s blockchain and AI-powered solutions all the while developing their own clinical research programme focusing on methylation events within Cancer and sports medicine. Shivom was picked for this project in particular because of their strong use case for data compliance and patient confidentiality. Additionally, the Horizon 20/20 programme will allow for recruiting a Clinical AI PhD student which will be supervised by Dr Darrol Baker.

“The molecular identification, characterization and secure patient consent for data use is a key measure within the realms of precision medicine and the prevention of ‘walling’ of genotypic and phenotypic data globally,” said Dr Darrol Baker, Head of Bioinformatics for Shivom. “Existing data in today’s digital universe offer tremendous opportunities to achieve this but for extracting insights and information from multiple heterogeneous and interdependent data in precision medicine, requires new systems analytics, moving beyond classical AI,  algorithmic or mechanical processes and validation against disease models. The Horizon 20/20 TranSYS research projects focus on Integrating Big Data and ICT Solutions and Translating Basic to Clinical Research. Shivom’s clinical blockchain AI solutions and the TranSys programme offer a unique 4-year window to explore and innovate global blockchain precision medicine.”

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Horizon 20/20
Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness.

Seen as a means to drive economic growth and create jobs, Horizon 2020 has the political backing of Europe’s leaders and the Members of the European Parliament. They agreed that research is an investment in our future and so put it at the heart of the EU’s blueprint for smart, sustainable and inclusive growth and jobs.

By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.

Horizon 2020 is open to everyone, with a simple structure that reduces red tape and time so participants can focus on what is really important. This approach makes sure new projects get off the ground quickly – and achieve results faster.

The EU Framework Programme for Research and Innovation will be complemented by further measures to complete and further develop the European Research Area. These measures will aim at breaking down barriers to create a genuine single market for knowledge, research and innovation.

For more information about Horizon 20/20  and it’s research programmes please visit https://ec.europa.eu/programmes/horizon2020/en

Recent Updates

View All

Cannabis

Shivom and TruTrace Technologies to Explore Clinical Solutions for Cannabis Market

Cannabis

Shivom Ventures Limited and TruTrace Technologies Inc. will explore a partnership to utilize both Shivom and TruTrace’s blockchain solutions in order to disrupt the global medicinal and recreational cannabis markets.CanabbisLONDON and TORONTO – June 25, 2019 – Shivom Ventures Limited (“Shivom”), a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, and TruTrace Technologies Inc. (CSE: TTT; OTC: TTTSF) (“TruTrace” or the “Company”), which has developed the first integrated blockchain platform that registers and tracks intellectual property for the cannabis industry, announced that the two companies have signed a letter of intent (“LOI”) to establish a strategic working relationship. The companies will explore a partnership to utilize both Shivom and TruTrace’s blockchain solutions in order to disrupt the global medicinal and recreational cannabis markets

Through the LOI, Shivom is entering into the booming cannabis market, which is projected to hit US$40 billion by 2024 – nearly triple the US$14.9 billion estimated to be spent this year, according to ArcView Market Research and cannabis industry analysis firm BDS Analytics.

“Shivom is excited to enter the cannabis market via a strategic partnership with TruTrace, which has developed the first integrated blockchain platform to register and track IP in the cannabis industry,” said Shivom CEO, Henry Ines. “As the industry is still in its early stages in terms of understanding and uncovering all of the medicinal benefits associated with the use of CBD, Shivom is keen to work with leading organizations in the space such as TruTrace to further uncover additional therapeutic benefits based on one’s genomic profile and unique personal health information. Shivom anticipates significant opportunities to collaborate with TruTrace and its partners to provide clinical research opportunities, medical insights and personalized healthcare products to consumers and patients within the global cannabis ecosystem.”

“Shivom has developed some very interesting technology that combines genomics, cryptography and AI, and we are excited to begin collaborating with them,” said TruTrace CEO, Robert Galarza. “We plan to explore development and integration opportunities to advance clinical research, and bring greater transparency, insights and viability to the legal medical and recreational cannabis industry.”

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:

Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About TruTrace Technologies

TruTrace Technologies has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry. TruTrace’s technology allows cannabis growers and breeders to identify and secure rights to their intellectual property. It also streamlines the administrative process and reduces the costs of genetic and mandatory quality-control testing for legal cannabis. TruTrace’s technology is proprietary, immutable and cryptographically secure, thereby establishing an accurate and permanent account for cannabis strains from ownership to market.

For more information about TruTrace Technologies please visit https://strainsecure.com/.

For More Information:

TruTrace Technologies Inc:
Robert Galarza, Chief Executive Officer and Director; Media Relations: Lori Harito, RNMKR Agency, 416-523-9602, lori@rnmkr.agency; Investor Inquiries: Swapan Kakumanu, Chief Financial Officer, 403-681-2549, swapan@trutrace.co

Disclaimer for Forward-Looking Information
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company, including the statements regarding: the expected synergies between TruTrace and Shivom; the expected benefits to the Company of the proposed relationship with Shivom; the expected date of entry into the Formal Agreement and conditions of closing to the transactions contemplated thereby; and that the Company and Shivom will successfully develop a solution that has a disruptive affect on the global recreational and medicinal cannabis industry. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking information necessarily involves known and unknown risks, including, without limitation, risks associated with general economic conditions; other parties involved in the Pilot Program; that sufficient numbers of researchers, clinicians, physicians, pharmacists, and patients will be available to participate in the Pilot Program; potential negative results of the Pilot Program; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States, and elsewhere; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry generally in Canada, the United States and elsewhere; and other risks. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information contained in this news release.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

Recent Updates

View All

Lympo

Shivom Partners with Lympo to Incentivise Fitness Goers

Lympo

Shivom in cooperation with Lympo will provide fitness goers token incentives when accomplishing daily fitness challenges and completing healthcare questionnaires this summer.

London, United Kingdom – May 23, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has partnered with Lympo, a free mobile app that allows you to earn money just for walking, running or even squatting. Complete these daily challenges, receive token rewards to be redeemed in-app for healthy lifestyle goods and services.

Through this partnership, Shivom and Lympo this summer will invite it’s users to complete select daily challenges via the Lympo app. This partnership is about conducting joint challenges which support each other’s respective ecosystems and missions centred around fitness, wellness and healthcare. The first co-branded challenge will be made available June 15th; asking users to complete a 4 km run and additionally sign up to Shivom’s platform and complete a health questionnaire in order to receive LYM and OMX tokens.

Shivom aims to onboard new customers onto Shivom’s platform, which provides customers with the ability to purchase DNA-based and other personalized healthcare products and services; to earn tokens via unique healthcare-related tasks and programs; and the opportunity to directly participate in and earn compensation if desired when providing data for clinical research. Shivom recently launched its ‘Shop 1.5’ — the first cut of Shivom’s consumer marketplace, which provides consumers with unique incentives and the ability to purchase direct-to-consumer genetic testing products either by OMX token or fiat payment. [hyperlink to press release].

The Lympo application is available for both iOS and Android and provides customers with a simple way to get rewarded for getting fit. Along with the incentives of data ownership, Lympo creates incentives through tokenized rewards. By participating in social challenges and documenting benchmarks, users can earn Lympo tokens, which they can exchange for products in the Lympo ecosystem. Jonušė, Chief Executive Officer of Lympo hopes this will have benefits at both a personal and a corporate level. Since the ICO, Lympo, has attracted 136,000 users, nearly 13,000 of whom are active daily, with over 1.6 million challenges completed. It’s already the number one fitness app in South Korea, and is partnering with major brands like Dallas Mavericks and Oxygen.

“We are thrilled to partner with Lympo to jointly sponsor daily fitness challenges and to offer token incentives via completion of select tasks on Lympo’s app and Shivom’s platform. Both organizations are focused on driving fitness and motivating individuals to make healthy lifestyle choices. There are considerable synergies as Lympo offers daily fitness challenges in a gamified manner while Shivom offers individualized healthcare products and services as well as the opportunity to monetize on the use of personal data for clinical research purposes. The partnership is also notable for the broader industry as two token projects converge for cross platform engagement and provide opportunities to earn and utilize both OMX and LYM native tokens — dynamics increasingly necessary for growing healthy token economies and ecosystems” according to Henry Ines, CEO of Shivom.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Lympo
Lympo is making the world healthier by rewarding people for exercising and leading healthier lives. With the help of blockchain technology and fitness gamification, users are rewarded with LYM tokens through the Lympo Run app, for completing walking and running challenges. These tokens can then be used to purchase quality sporting goods by top global brands in Lympo Shop – the first-ever online shop to accept fitness token payments.

We are actively building a complete data-sharing ecosystem, which in the future will connect fitness and wellness stakeholders (personal trainers, gyms, sports events, brands) with users via a blockchain based reward system, linked to users’ health and fitness data. We will also offer a place to collect, store and monetize this valuable data from a variety of health and fitness tracking apps or wearables.

Ultimately, the goal is to create a win-win situation for each platform participant – the users will be able to monetize their health and fitness data via the LYM utility token and the businesses, in return, will receive access to a tech-savvy community, passionate about healthy living.

For more information about Lympo please visit here

Recent Updates

View All

Shivom

Here’s How Shivom Chooses it’s Marketplace Partners

Shivom

This week, Shivom will launch its first iteration of our direct-to-consumer health management marketplace.  In this post, we will be providing information to the community and prospective partners about how we determine which products and companies are listed on our platform.

Shivom’s mission is to not only optimize how DNA is shared, secured and analysed but to bring exponential value to our end-users. With this mission comes the responsibility to make some pretty tough decisions through and through. One of these decisions is choosing which companies Shivom would want to interact with within our eco-system. When our team started working on ‘Shop 1.5’ Shivom understood that we shouldn’t strive to be just a marketplace promoting every type of genetic testing product we could get our hands on. This business model not only has problems with scalability but additionally lowers the quality or value we bring to our audience. For these reasons and many more, our team developed quality control and criteria which are used to decide which partners should be able to gain entry to the marketplace.

The first part of our review is about companies’ data privacy and security policies. The first question we ask is, do you share data with third-parties? The second question we ask is, do you sell or utilise the user’s data in order to generate revenue? If the answer is yes to either one of these questions, straight off the back the company would be eliminated from being able to join our marketplace.

In the second part of the review, our team will determine the quality of the report and determine whether it brings any value or if it is B*** S***. A Great example of this is when I recently saw on a competitor’s website that they were sequencing a user’s DNA in order to find out what kind of t-shirt looked best on them (v-neck or crew).

The third part of our review is whether the product and or company brings value to the eco-system. For example, if someone recently purchased Living DNA’s 3-in-1 Ancestry Kit they might also be interested in learning about their nutrition and cholesterol. Instead of having to purchase an entire kit we look at products which allow people to use their Raw Genetic data gained from the Ancestry KIt instead of having to re-swab, prick or take a faecal sample all over again. Additionally, we are also looking at which products are complementary to each other and could go hand-in-hand

In case you were wondering what the reasons were for choosing Vitl, Living DNA and Chronomics for our first iteration, I’ve included below an in-depth explanation.

Vitl
Vitl products not only have a high rate of positive customer feedback (e.g. 91% of customers rated Vitl products as ‘Excellent’ on Trustpilot), the team is comprised
of experts in their field; such as geneticists, nutritionists who understand the science and the practical aspects of healthy nutrition. Vitl uses the latest innovative technologies, such as; artificial intelligence. Additionally, the company uses credible vendors and laboratories for their tests(e.g. UKAS-accredited and CQC-registered blood testing facilities) as well as Illumina CSPro Certified Service Providers in Europe and the USA for DNA testing. Whilst other brands may test for a larger number of less well-researched traits, Vitl emphasizes quality over quantity. They only cover traits based on the strongest, peer-reviewed evidence to ensure users are getting the most reliable results.

Lastly, similar to Shivom’s philosophy of combining different omics technologies to gain insight, Vitl enables the integration of DNA data alongside blood and dietary results and lifestyle information. This is important because supplement recommendations or lifestyle advice cannot be made on DNA information alone, but taken alongside current blood vitamin levels and diet that are measured in a longitudinal way.

Living DNA
Living DNA launched back in 2016 as a collaboration of more than 100 scientists, researchers and genetic experts. We added Living DNA as a partner to our ecosystem because they provide precise ethnic estimates of ancestry testing. The 3-in-1 test covers the biggest number of genetic populations, which translates to the most accurate genetic percentages and offers unrivalled worldwide regional and sub-regional detail. The test incorporates three separate tests in one, giving the customer more for their money than any other ancestry tests on the market right now.

Additionally, instead of just getting your basic family ancestry (autosomal DNA), you also get an analysis along your mother line (derived from mitochondrial DNA) and your father line (derived from the male-specific y-chromosome). Living DNA is a holder of ISO:27001 certification, which demonstrates good protection and security for personal and genetic data. As DNA samples are only connected to unique ID numbers, not even its staff members will know the identity of its users. The company works with “Show Racism the Red Card,” a group that fights racism to provide a safe space to reduce racist ideas and attitudes. Lastly, Living DNA provides the raw data of all test results which can be used on the Shivom precision medicine platform to foster research and fight rare diseases.

Chronomics
Epigenetic testing is relatively new to the direct-to-consumer testing market. We partnered with Chronomics because of their impeccable experience in this field. Our CSO, Dr Axel Schumacher is one of the many pioneers of epigenetics and worked alongside some of the Chronomics team members.

Epigenetics is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself. Epigenetic testing offers additional value to genomic testing, in particular, allowing individuals to analyse how environmental and lifestyle choices affect the body and how these patterns change over time. By monitoring epigenetic patterns, it is possible to collect actionable insight allowing for a personalized improvement plan. Most importantly, Chronomics provides users with the ability to gain access to their raw data which can be managed, stored and monetized on Shivom.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recent Updates

View All

Vitl

Shivom Adds Vitl to the Marketplace, Offering Customers Vitamin & Cholesterol Blood Tests

Vitl

The VITL Vitamin and Cholesterol Blood Test will provide Shivom’s customers with the ability to track and improve key health markers so you can feel your best more often.

London, United Kingdom – May 14, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has teamed up with Vitl who have partnered with experienced doctors, geneticists, biomedical scientists and expert nutritionists from leading organisations around the world, including King’s College London, The Institute for Optimum Nutrition and the European Nutrition Leadership Platform; to offer Vitl’s Vitamin and Cholesterol Blood Test within Shivom’s marketplace. Through this affiliation, Shivom’s customers can track and improve key health markers so you can feel your best more often.

The blood kit which has been developed by Vitl enables consumers via at home simple finger-prick blood test you’ll get a thorough analysis of the key nutrients that have the greatest impact on wellbeing and long-term health. This can be done from the comfort of your own home with no large needles or waiting rooms. The customer will also receive personalised dietary and lifestyle recommendations from a qualified nutritionist, and a bespoke pack of vitamins tailored to your results.

For a limited period of time, Shivom plans to offer unique incentives ranging from token rewards to discounted reports and genetic counselling sessions via Shivom partners and affiliates. “In addition to Living DNA’s ancestry kits, we are now pleased to also offer Vitl’s Vitamin and Cholesterol Blood Test kit, which will provide our customers with deep insights, such as understanding which nutrients are most impactful for well-being and long term health, and the ability to receive customized dietary and lifestyle recommendations from a qualified nutritionist. Customized vitamin supplements will also now be possible to offer our customers based on their personal health and genomic profile. As is the case with all of our curated products, Vitl’s products are world class, grounded in science and are manufactured and processed in accordance with leading international standards and certifications.” Says Henry Ines, CEO of Shivom.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Vitl
We understand finding the time to stay healthy is increasingly difficult when you lead a busy, exciting life. So we created VITL to help do the hard work for you. Reinventing the approach to daily nutrition, our products are developed by VITL’s team of leading experts using the highest quality, sustainably sourced ingredients to help you stay healthy and feel great.

Thoughtfully designed to fit effortlessly and conveniently with your busy day, we’re on a mission to make staying healthy a little more achievable.

Love life? #LiveLifeBetter with VITL

For more information about Vitl please visit here

Recent Updates

View All

Ancestry Kit_Living_DNA_Shivom

Shivom Adds Living DNA to the Marketplace, Offering Customers a 3-in-1 ancestry Kit

Ancestry Kit_Living_DNA_Shivom

Living DNA’s 3-in-1 ancestry kit will provide Shivom’s customers with the ability to trace their origins back via maternal ancestors, and see how they moved around the world over thousands of years.

London, United Kingdom – April 15, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has now been approved as an affiliate of Living DNA. Through this affiliation, Shivom will redirect customers to the Living DNA website in order to purchase their 3-in-1 ancestry kit.

The ancestry kit which has been developed by Living DNA enables consumers to discover their ancestry from around the world via a simple cheek swab, providing exceptional regional details. Many of their customers have used this opportunity to travel to their ancestral homelands. Living DNA can show you your recent family ancestry covering up to 15 generations, and your deep ancestry with Motherline and Fatherline (if male) results. Additionally, the company have developed an improved Single nucleotide polymorphisms (SNP) genotyping platform that has been tailored to match the technical requirements of the different statistical methodologies they use to analyse customer data. Sirius, the new chip, has been designed using the Axiom® technology from Affymetrix / Thermo Scientific, which allows great flexibility to match every feature of the chip to their products.

“We are excited to offer Living DNA’s kits within our marketplace. Living DNA, along with parent company DNA Worldwide Group, shares the same high standards of excellence and commitment to consumer data ownership and security as Shivom. Living DNA’s kit is not only rated one of the best ancestry kits on the market, but they are also accredited and certified by leading international standards.” Says Henry Ines, CEO of Shivom.

For more information about Shivom please visit:
https://www.shivom.io

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Living DNA
Living DNA is a high definition of DNA testing that challenges the concept of race and tackles ideas of separation through our ‘One Family, One World’ education programmes. With 75% of clients living overseas, we do this globally.

Presenting self-truth and letting science talk helps people change their lives. Putting ancestry into context allows people to celebrate not only how unique they are but also understand how we are all connected going back through history.

For more information about Living DNA please visit:
www.livingDNA.com

Recent Updates

View All

Cleveland Clinic-Family-Care-Path-Shivom

Shivom Partners with Family Care Path a Spin-Off Company from Cleveland Clinic

Cleveland Clinic-Family-Care-Path-Shivom

Family Care Path’s clinically-validated MyLegacy and CarePathConnect application will provide new ways for Shivom’s customers to take action on their genetic risk for certain hereditary conditions.

London, United Kingdom – April 2, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, and Family Care Path (FCPI), a spin-off company from Cleveland Clinic adapting and marketing web-based clinical decision support applications, are collaborating to integrate FCPI’s MyLegacy application within Shivom’s marketplace. Through collaboration, Shivom’s customers can gain access to a personalised health risk profile and genomic counselling sessions which provide end-users with coaching to take proactive steps against hereditary conditions found within their genetic data.

FCPI has established an international telegenetic counselling network, branded CarePathConnect, which provides patients with the ability to privately and securely discuss their genetic health risk conditions with genetic counsellors and learn about the benefits and limitations of genetic testing via a HIPAA-compliant web-based video platform. The company exclusively licensed the family history collection and disease risk assessment tool from Cleveland Clinic, branded MyLegacy, which uses proprietary algorithms based on practice guidelines developed by the Cleveland Clinic Genomic Medicine Institute.

“Access to your genetic information is really just the beginning — using that information in combination with genetic counselling allows the necessary preventative measures to prevent serious health complications,” said Henry Ines, CEO of Shivom. “Our collaboration with Family Care Path enables Shivom’s customers to access their genetic information using a clinically validated programme to help them make lifestyle changes which seek to prevent or suppress hereditary conditions.”

The pilot for this collaboration will enable Shivom customers to access the FCP MyLegacy application and schedule a virtual genomic counselling session. Both clinical and non-clinical counselling sessions will be explored and processes will be established to ensure that customers are able to utilise both data collected from the FCP risk assessment tool as well as any genomic or other ‘omics’ reporting facilitated by Shivom subject to patient consent and permissions. Shivom also plans to arrange for its OMX token to be utilised as a means of payment and incentives for accessing counselling sessions and related services. The partnership marks a critical step in the roadmap for Shivom as it onboards key partners and services on its platform/marketplace to further demonstrate utility for its token.

“We are excited to collaborate with Shivom on this innovative effort. Working with Shivom will help their customers have a deeper understanding of their genetic information through testing, counselling and the ties to family health history” says David McKee, President and CEO of Family Care Path.

For more information about Shivom’s direct-to-consumer solutions please click here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Shivom Social Channels:
● Official Homepage: shivom.io
● Twitter (English): @projectshivom
● Youtube: Shivom’s Channel
● Telegram: Shivom Announcements
● Facebook: @projectshivom
● Instagram: @projectshivom
● Medium: Shivom Official
● LinkedIn: @projectshivom

About Family Care Path
Family Care Path develops, adapts and markets web-based clinical software applications designed to improve patient outcomes, increase physician and clinical process efficiency, and interface with a variety of electronic health records.

Many exciting concepts for healthcare applications remain isolated within the development environment. Our company’s mission is to identify these opportunities and develop software solutions utilising industry standard protocols, to enable widespread adoption.

We utilise the latest technology to develop secure and scalable applications to improve the quality of healthcare and reduce cost. Leveraging industry standard technologies such as Microsoft Cloud and both the SMART® and HL7® FHIR® open standards, Family Care Path creates applications which can seamlessly communicate with all electronic health record systems.

For more information about Family Care Path please visit:
www.familycarepath.com

Recent Updates

View All